Why the Phoslock share price could head lower in 2019

Phoslock Environmental Technologies Ltd (ASX: PET)

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Phoslock Environmental Technologies Ltd (ASX: PET) share price is down more than 25% this week after the "environmental technology" business handed in its 4C quarterly cash flow report.

For the quarter Phoslock reported a net operating cash loss of $3.84 million on sales of $4.65 million in a weak result it put down to large raw material procurement costs.

It's sticking to guidance for calendar 2019 revenue to come in between $27 million to $30 million. The company had $14.6 million cash on hand at the quarter end. 

It reports that its Phoslock product can be used to treat polluted water masses and it's particularly targeting China for expansion due to its serious water pollution problems. 

It reports that it currently holds 3,000 tonnes of Phoslock in China and across the globe, with it expecting to sell between 4,000 to 5,000 tonnes over the December quarter. It boasts that it has a "$200 million" pipeline of Phoslock projects in China. 

Based 0n 562.5 million shares issue at a 98 cents share price today it has an eye watering $551 million valuation on around 19x forecast revenues. It reported profit of just $1 million in fiscal 2019. 

It looks the kind of story stock likely to attract less-sophisticated retail investors even though it's overvalued. I expect its shares will continue to track lower through 2019 as it doesn't look the kind of business to interest credible investors.

Other 'story' stocks that have soared on hype only to tumble on financial reality include the likes of pot stocks Auscann Group Holdings Ltd (ASX: AC8) and Cann Group Ltd (ASX: CAN). While iSignthis Ltd (ASX: ISX) remains suspended while both securities regulators look into alleged irregularities and disclosure failings at the same time. 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »